SAVOR: La baisse de la glycémie dans le haut risque cardiovasculaire, pas d'effet clinique et peut-être un risqueCardiologie cardinale. 2013, Vol 7, Num 56, issn 1960-1646, p. 69Conference Paper

Carbon-14 labeling of Saxagliptin (BMS-477118)KAI CAO; BONACORSI, Samuel J; BALASUBRAMANIAN, Balu et al.Journal of labelled compounds & radiopharmaceuticals. 2007, Vol 50, Num 13-14, pp 1224-1229, issn 0362-4803, 6 p.Article

Saxagliptin overview: special focus on safety and adverse effectsALI, Shamsa; FONSECA, Vivian.Expert opinion on drug safety. 2013, Vol 12, Num 1, pp 103-109, issn 1474-0338, 7 p.Article

Saxagliptin: A New Dipeptidyl Peptidase 4 Inhibitor for Type 2 DiabetesBORJA-HART, Nancy L; WHALEN, Karen L.The Annals of pharmacotherapy. 2010, Vol 44, Num 6, pp 1046-1053, issn 1060-0280, 8 p.Article

Tolerability of Dipeptidyl Peptidase-4 Inhibitors: A ReviewRICHARD, Kathleen R; SHELBURNE, Jamie S; KIRK, Julienne K et al.Clinical therapeutics. 2011, Vol 33, Num 11, pp 1609-1629, issn 0149-2918, 21 p.Article

Heart Failure, Saxagliptin, and Diabetes Mellitus: Observations from the SAVOR-TIMI 53 Randomized TrialSCIRICA, Benjamin M; BRAUNWALD, Eugene; POLLACK, Pia S et al.Circulation (New York, N.Y.). 2014, Vol 130, Num 18, pp 1579-1588, issn 0009-7322, 10 p.Article

Incrétines: les premiers résultats des études d'intervention cardiovasculaires : Les nouveaux médicaments du diabète = The incretin-based-therapy: the first results of the cardiovascular intervention studiesKREMPF, M.La Lettre du cardiologue. 2014, Num 473, pp 14-18, issn 0761-5035, 5 p.Article

Prise en charge d'un diabète insulinotraité Intérêt des IDPP4COSSON, Emmanuel.Diabète & obésité. 2013, Vol 8, Num 70, pp 178-181, issn 1957-5238, 4 p.Article

Effect of rifampicin on the pharmacokinetics and pharmacodynamics of saxagliptin, a dipeptidyl peptidase-4 inhibitor, in healthy subjectsUPRETÏ, Vijay V; BOULTON, David W; LI LI et al.British journal of clinical pharmacology. 2011, Vol 72, Num 1, pp 92-102, issn 0306-5251, 11 p.Article

Saxagliptin: A Clinical Review in the Treatment of Type 2 Diabetes MellitusKANIA, Deanna S; GONZALVO, Jasmine D; WEBER, Zachary A et al.Clinical therapeutics. 2011, Vol 33, Num 8, pp 1005-1022, issn 0149-2918, 18 p.Article

Inhibiteurs de la dipeptidyl-peptidase-4: place thérapeutique actuelle, perspectives et questions non résoluesBLICKLE, Jean-Frédéric.MT. Médecine thérapeutique. 2010, Vol 16, Num 2, pp 105-114, issn 1264-6520, 10 p.Article

Efficacy and Safety of Dipeptidyl Peptidase-4 Inhibitors in Type 2 Diabetes: Meta-AnalysisPARK, Haesuk; PARK, Chanhyun; KIM, Yoona et al.The Annals of pharmacotherapy. 2012, Vol 46, Num 11, pp 1453-1469, issn 1060-0280, 17 p.Article

Dipeptidyl Peptidase-4 Inhibitors for the Treatment of Type 2 Diabetes MellitusNEUMILLER, Joshua J; WOOD, Lindy; CAMPBELL, R. Keith et al.Pharmacotherapy. 2010, Vol 30, Num 5, pp 463-484, issn 0277-0008, 22 p.Article

Dipeptidyl peptidase IV inhibitors and the incretin system in type 2 diabetes mellitusLANGLEY, Alissa K; SUFFOLETTA, Terri J; JENNINGS, Heath R et al.Pharmacotherapy. 2007, Vol 27, Num 8, pp 1163-1180, issn 0277-0008, 18 p.Article

Efficacy of saxagliptin as an add-on to oral monotherapy in the phase 3 clinical development program: Predictive factors of the treatment response in type 2 diabetesGAUTIER, J.-F; SAUVANET, J.-P.Annales d'endocrinologie. 2011, Vol 72, Num 4, pp 287-295, issn 0003-4266, 9 p.Article

Saxagliptin versus glipizide as add-on therapy to metformin: assessment of hypoglycemiaMINTZ, Matthew L; MINERVINI, Gianmaria.Current medical research and opinion. 2014, Vol 30, Num 5, pp 761-770, issn 0300-7995, 10 p.Article

Gliptines: troubles graves pancréatiques, cutanésLa Revue Prescrire. 2014, Vol 34, Num 363, issn 0247-7750, p. 22Article

Dipeptidyl Peptidase-4 Inhibition: Linking Chemical Properties to Clinical SafetyMATTEUCCI, E; GIAMPIETRO, O.Current medicinal chemistry. 2011, Vol 18, Num 31, pp 4753-4760, issn 0929-8673, 8 p.Article

The design and rationale of the Saxagliptin Assessment of Vascular Outcomes Recorded in patients with diabetes mellitus-Thrombolysis in Myocardial Infarction (SAVOR-TIMI) 53 StudySCIRICA, Benjamin M; BHATT, Deepak L; RAZ, Itamar et al.The American heart journal. 2011, Vol 162, Num 5, pp 818-825, issn 0002-8703, 8 p.Article

saxagliptine ^(ONGLYZA°) seule ou associée: Pas moins de complications, peut-être plus d'insuffisances cardiaquesLa Revue Prescrire. 2014, Vol 34, Num 366, issn 0247-7750, p. 256Article

Gliptins: severe pancreatic and cutaneous disordersPrescrire international (Paris). 2014, Vol 23, Num 149, issn 1167-7422, p. 128Article

Saxagliptin and Cardiovascular Outcomes in Patients with Type 2 Diabetes MellitusSCIRICA, Benjamin M; BHATT, Deepak L; CAVENDER, Matthew A et al.The New England journal of medicine. 2013, Vol 369, Num 14, pp 1317-1326, issn 0028-4793, 10 p.Article

Kinetic and Mechanistic Insight into the Thermodynamic Degradation of SaxagliptinSCOTT JONES, G; SAVAGE, Scott A; IVY, Sabrina et al.Journal of organic chemistry. 2011, Vol 76, Num 24, pp 10332-10337, issn 0022-3263, 6 p.Article

La saxagliptine (Onglyza^®) - un nouvel inhibiteur de la DPP-4 pour le traitement oral du diabète de type 2HERMANS, M. P.Louvain médical. 2010, Vol 129, Num 8, pp 302-304, issn 0024-6956, 3 p.Article

Clinical utility of dipeptidyl peptidase-4 inhibitors: a descriptive summary of current efficacy trialsGRUNBERGER, George.European journal of clinical pharmacology. 2014, Vol 70, Num 11, pp 1277-1289, issn 0031-6970, 13 p.Article